Kenvue’s Pending $40 Billion Merger With Kimberly-Clark Creates a Near-$3 Per Share Arbitrage Opportunity

Corporate ActionEarnings Impact 4
โดย The Motley Fool·Read original
Summary · why it matters

Kenvue, the consumer health spinoff from Johnson & Johnson, is trading around $18.32 per share, well below the $21.01 per share total consideration offered in its pending $40 billion mega-merger with Kimberly-Clark. The deal, already approved by shareholders of both companies but still subject to foreign regulatory approvals, would give Kenvue investors $3.50 in cash plus 0.14625 Kimberly-Clark shares for each Kenvue share held. The combined company expects to capture roughly $2.1 billion in run rate cost synergies by giving local markets full profit-and-loss ownership while leveraging Kimberly-Clark’s global supply chain. Kenvue, a Dividend King with 63 consecutive years of payout increases, currently yields 4.53% and owns iconic brands such as Tylenol, Listerine, Neutrogena, and Band-Aid, while its first-quarter revenue rose 4.5% year over year to $3.9 billion and earnings per share jumped 47% to $0.25.

Impact on stocks 4

Consumer Staples▲ · 2 stocks
Kimberly-Clark Corporation
KMB
▲ PositiveCapitalrelevance

Kimberly-Clark is the acquirer in a $40B merger expected to generate $2.1B in cost synergies.

Kenvue Inc.
KVUE
▲ PositiveCapitalrelevance

Kenvue shareholders receive $3.50 cash plus 0.14625 KMB shares per share, creating an arbitrage opportunity above current price.

Biotech & Genomic Medicine▲ · 1 stocks
Artificial Intelligence▲ · 1 stocks
© 2026 MarketDXNews